These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1402295)

  • 1. The effect of some macromolecular ionic complexes on the pharmacokinetics and -dynamics of ocular cyclopentolate in rabbits.
    Huupponen R; Kaila T; Saettone MF; Monti D; Ilsalo E; Salminen L; Oksala O
    J Ocul Pharmacol; 1992; 8(1):59-67. PubMed ID: 1402295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucoadhesive ophthalmic vehicles: evaluation of polymeric low-viscosity formulations.
    Saettone MF; Monti D; Torracca MT; Chetoni P
    J Ocul Pharmacol; 1994; 10(1):83-92. PubMed ID: 8207347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations and ocular effects of cyclopentolate after ocular application of three formulations.
    Lahdes K; Huupponen R; Kaila T; Monti D; Saettone MF; Salminen L
    Br J Clin Pharmacol; 1993 May; 35(5):479-83. PubMed ID: 8512760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic absorption of ocular cyclopentolate in children.
    Lahdes K; Huupponen R; Kaila T; Ali-Melkkilä T; Salminen L; Saari M
    Ger J Ophthalmol; 1992; 1(1):16-8. PubMed ID: 1477610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular effects and systemic absorption of cyclopentolate eyedrops after canthal and conventional application.
    Lahdes KK; Huupponen RK; Kaila TJ
    Acta Ophthalmol (Copenh); 1994 Dec; 72(6):698-702. PubMed ID: 7747578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic and ocular absorption and antagonist activity of topically applied cyclopentolate in man.
    Haaga M; Kaila T; Salminen L; Ylitalo P
    Pharmacol Toxicol; 1998 Jan; 82(1):19-22. PubMed ID: 9527641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of hyaluronan as a drug carrier to enhance the bioavailability of extended release ophthalmic formulations. Hyaluronan-timolol ionic complexes as a model case.
    Battistini FD; Tártara LI; Boiero C; Guzmán ML; Luciani-Giaccobbe LC; Palma SD; Allemandi DA; Manzo RH; Olivera ME
    Eur J Pharm Sci; 2017 Jul; 105():188-194. PubMed ID: 28506871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea.
    Yenice I; Mocan MC; Palaska E; Bochot A; Bilensoy E; Vural I; Irkeç M; Hincal AA
    Exp Eye Res; 2008 Sep; 87(3):162-7. PubMed ID: 18675411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effects on accommodative and pupillary responses by topical application of cyclopentolate hydrochloride].
    Ohmi G; Kinoshita H; Kinoshita S
    Nippon Ganka Gakkai Zasshi; 1991 Nov; 95(11):1099-104. PubMed ID: 1759650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Absorption of Cyclopentolate and Adverse Events After Retinopathy of Prematurity Exams.
    Mitchell A; Hall RW; Erickson SW; Yates C; Lowery S; Hendrickson H
    Curr Eye Res; 2016 Dec; 41(12):1601-1607. PubMed ID: 27159349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of topical 1% cyclopentolate hydrochloride on tear production, pupil size, and intraocular pressure in healthy Beagles.
    Costa D; Leiva M; Coyo N; Laguna F; Ríos J; Peña Gimenez MT
    Vet Ophthalmol; 2016 Nov; 19(6):449-453. PubMed ID: 26475235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular pharmacokinetics and pharmacodynamics of phenylephrine and phenylephrine oxazolidine in rabbit eyes.
    Chien DS; Schoenwald RD
    Pharm Res; 1990 May; 7(5):476-83. PubMed ID: 2367315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic differences between ocular inserts and eyedrops.
    Friedrich SW; Saville BA; Cheng YL; Rootman DS
    J Ocul Pharmacol Ther; 1996; 12(1):5-18. PubMed ID: 8925396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pupillary dilatation with single eyedrop mydriatic combinations.
    Apt L; Henrick A
    Am J Ophthalmol; 1980 Apr; 89(4):553-9. PubMed ID: 7369319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and ocular pharmacokinetics of hyaluronan acid-modified mucoadhesive liposomes.
    Lin J; Wu H; Wang Y; Lin J; Chen Q; Zhu X
    Drug Deliv; 2016 May; 23(4):1144-51. PubMed ID: 25533876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 0.1% cyclopentolate or 10% phenylephrine on pupil diameter and accommodation.
    Mordi J; Tucker J; Charman WN
    Ophthalmic Physiol Opt; 1986; 6(2):221-7. PubMed ID: 3748569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible allergic reactions to cyclopentolate hydrochloride: case reports with literature review of uses and adverse reactions.
    Jones LW; Hodes DT
    Ophthalmic Physiol Opt; 1991 Jan; 11(1):16-21. PubMed ID: 2034449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.
    Acheampong AA; Shackleton M; Tang-Liu DD
    Drug Metab Dispos; 1995 Jul; 23(7):708-12. PubMed ID: 7587958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of the mydriatic response to tropicamide by bioadhesive polymers.
    Herrero-Vanrell R; Fernandez-Carballido A; Frutos G; Cadórniga R
    J Ocul Pharmacol Ther; 2000 Oct; 16(5):419-28. PubMed ID: 11110033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyaluronic acid-coated niosomes facilitate tacrolimus ocular delivery: Mucoadhesion, precorneal retention, aqueous humor pharmacokinetics, and transcorneal permeability.
    Zeng W; Li Q; Wan T; Liu C; Pan W; Wu Z; Zhang G; Pan J; Qin M; Lin Y; Wu C; Xu Y
    Colloids Surf B Biointerfaces; 2016 May; 141():28-35. PubMed ID: 26820107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.